✦ LIBER ✦

(F2) Granulocyte colony-stimulating factor (G-CSF) in the treatment of myelodysplastic syndromes (MDS)

✍ Scribed by P. Greenberg; R. Negrin; A. Nagler

Book ID: 113239452
Publisher: Elsevier Science
Year: 1991
Tongue: English
Weight: 133 KB
Volume: 15
Category: Article
ISSN: 0145-2126
DOI: 10.1016/0145-2126(91)90371-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erythropoietin, with and without granulo

Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients

✍ K Miller 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Treatment of “high risk” myelodysplastic

Treatment of “high risk” myelodysplastic syndromes (MDS) with idarubicin and cytosine arabinoside, supported by granulocyte-macrophage colony stimulating factor (GM-CSF)

✍ T. Economopoulos; E. Papageorgiou; A. Parharidou; M. Constantinidou; J. Dervenou 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 183 KB

Low-dose cytarabine (LD-AraC) plus recom

Low-dose cytarabine (LD-AraC) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for myelodysplastic syndromes (MDS)

✍ Kikuchi, A; Ohashi, H; Hanada, R; Yamamoto, K 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 68 KB

Granulocyte-macrophage colony-stimulatin

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia

✍ Bengt Sallerfors; Tor Olofsson 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 770 KB

Effects of prolonged treatment of myelod

Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor

✍ Peter Greenberg; Robert Negrin; Arnon Nagler; Timothy Donlon; Martha Vincent 📂 Article 📅 1990 🏛 AlphaMed Press 🌐 English ⚖ 633 KB

Fludarabine, cytarabine, and granulocyte

Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes

✍ Felicetto Ferrara; Franco Leoni; Antonio Pinto; Salvatore Mirto; Enrica Morra; V 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## BACKGROUND. The prognosis of patients with high risk myelodysplastic syndromes (MDS) (i.e., refractory anemia with excess of blasts [RAEB] and refractory anemia with excess of blasts in transformation [RAEB-t]) usually is poor. The combination of fludarabine, cytarabine, and granulocyte-colony